DVAX Insider Trading

Insider Ownership Percentage: 2.98%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Dynavax Technologies Insider Trading History Chart

This chart shows the insider buying and selling history at Dynavax Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3-$20M-$10M$0$10M$20MTotal Insider BuyingTotal Insider Selling

Dynavax Technologies Share Price & Price History

Current Price: $10.72
Price Change: Price Increase of +0.05 (0.47%)
As of 07/18/2025 05:00 PM ET

This chart shows the closing price history over time for DVAX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AugSepOctNovDecJanFebMarAprMayJunJul$10.72Closing price on 07/19/25:

SEC Filings (Institutional Ownership Changes) for Dynavax Technologies (NASDAQ:DVAX)

96.96% of Dynavax Technologies stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at DVAX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$59kbought$1.50MsoldQ3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3-$100M$0$100MTotal InflowsTotal Outflows
Dynavax Technologies logo
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
Read More on Dynavax Technologies

Today's Range

Now: $10.72
Low: $10.63
High: $10.83

50 Day Range

MA: $10.10
Low: $9.40
High: $10.90

52 Week Range

Now: $10.72
Low: $9.22
High: $14.63

Volume

928,420 shs

Average Volume

2,145,645 shs

Market Capitalization

$1.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Who are the company insiders with the largest holdings of Dynavax Technologies?

Dynavax Technologies' top insider shareholders include:
  1. Andrew A F Hack (Director)
  2. Robert Janssen (CMO)
  3. Francis Cano (Director)
  4. David F Novack (COO)
  5. Justin Burgess (CAO)
Learn More about top insider investors at Dynavax Technologies.

Who are the major institutional investors of Dynavax Technologies?

Dynavax Technologies' top institutional investors include:
  1. Chicago Capital LLC — 4.35%
  2. Exchange Traded Concepts LLC — 0.11%
  3. State of Alaska Department of Revenue — 0.06%
  4. Palumbo Wealth Management LLC — 0.01%
  5. GAMMA Investing LLC — 0.00%
Learn More about top institutional investors of Dynavax Technologies stock.

Which institutional investors are selling Dynavax Technologies stock?

During the last quarter, DVAX stock was sold by these institutional investors:
  1. Chicago Capital LLC
  2. Palumbo Wealth Management LLC
  3. GAMMA Investing LLC
  4. State of Alaska Department of Revenue

Which institutional investors are buying Dynavax Technologies stock?

Within the previous quarter, DVAX stock was purchased by institutional investors including:
  1. Exchange Traded Concepts LLC